Domatinostat

DRUG3 trials

Sponsors

Royal Marsden NHS Foundation Trust, The Netherlands Cancer Institute, H. Lee Moffitt Cancer Center and Research Institute

Conditions

CancerGI CancerMalignant Melanoma Stage IIIOsteosarcomaSarcoma

Phase 1

Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma

CompletedNCT04133948

The Netherlands Cancer InstituteMalignant Melanoma Stage III

Start: 2020-01-07End: 2024-11-26Updated: 2025-03-10

Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma

RecruitingNCT07725380

H. Lee Moffitt Cancer Center and Research InstituteOsteosarcoma, Sarcoma

Start: 2026-07-15End: 2031-08-01Target: 74Updated: 2026-09-03

Phase 2

Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE)

Royal Marsden NHS Foundation TrustCancer, GI Cancer

Start: 2019-01-11End: 2021-11-30Target: 75Updated: 2019-02-05

Related Papers

Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE.

2024-03-214 citations

The interferon-gamma (IFN-y) signature from baseline tumor material predicts pathologic response after neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma.

Journal of Clinical Oncology2022-06-0113 citations

P01.15 Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in macroscopic stage III melanoma patients stratified according to interferon-gamma (IFN-gamma) signature – the DONIMI study

2020-10-012 citations

Personalized combination of neoadjuvant domatinostat, nivolumab and ipilimumab in macroscopic stage III melanoma patients stratified according to the interferon-gamma signature: The DONIMI study.

Journal of Clinical Oncology2020-05-2011 citations

Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).

2019-11-0862 citations